XM does not provide services to residents of the United States of America.
C
C

Clariant

News

Alfa Laval, Ferrari NV, Swedbank

EUROPE RESEARCH ROUNDUP-Alfa Laval, Ferrari NV, Swedbank July 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfa Laval, Ferrari NV and Swedbank, on Tuesday. HIGHLIGHTS * Alfa Laval ALFA.ST : JP Morgan raises target price to SEK 390 from SEK 385 * Ferrari NV RACE.MI : HSBC raises target price to EUR 385 from EUR 368 * Harworth Group Plc HWG.L : Peel Hunt raises target price to 195p from 165p * Moonpig Group MOONM.L : HSBC raises
A
A
A
B
B
B
B
B
B
C
C
C
E
E
F
H
H
I
P
P
S
V
A
A
D
S
S

Pearson, Softcat, Trelleborg

EUROPE RESEARCH ROUNDUP- Pearson, Softcat, Trelleborg July 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Pearson, Softcat and Trelleborg, on Friday. HIGHLIGHTS * Aker BP ASA AKRBP.OL : Jefferies cuts target price to NOK 340 from NOK 345 * GSK GSK.L : Citigroup cuts target price to 1900p from 2120p * Pearson PSON.L : Deutsche Bank raises target price to 1052p from 1050p * Softcat Plc SCTS.L : Jefferies cuts target price to 1,490p
A
A
B
C
C
D
D
E
E
G
I
K
N
N
P
T
T
T
V
W
A
D
Y

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S

Clariant seen rising after Berenberg starts coverage with 'buy'

BUZZ-Clariant seen rising after Berenberg starts coverage with 'buy' ** Shares in Clariant CLN.S are seen up 1.4% in Julius Baer premarket indications after Berenberg initiates the Swiss speciality chemicals firm with "buy", saying it sees "a clearer path to higher margins" ** The broker says it believes macro headwinds have masked the progress Cla
C
J
I

GS sees uneven recovery for European chemicals; ups Clariant, cuts Akzo

BUZZ-GS sees uneven recovery for European chemicals; ups Clariant, cuts Akzo ** Goldman Sachs favours consumer ingredient and gasses cos over diversified chemicals and paint makers based on pricing power, as the European chemicals sector faces an uneven recovery ** GS notes Europe's STOXX chemicals sub-index .SX4P is up 13% from its October 2023 tr
A
B
C
C
G
L
S
U
A
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.